U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935174) titled '^68Ga-grazytracer PET for In Vivo Visualization of Immune Cell Effector Functions' on July 06.
Brief Summary: This is a prospective, single-center, exploratory clinical study designed to evaluate the feasibility, safety, and clinical utility of ^68Ga-grazytracer positron emission tomography (PET) for noninvasive in vivo visualization of immune cell effector function in patients with cancer and autoimmune diseases. ^68Ga-grazytracer is a granzyme B (GZMB)-targeted PET radiotracer developed to visualize cytotoxic immune activation.
Approximately 60-80 adult participants will be enrolled in two study cohorts: (1) patients with maligna...